Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program

By /

Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.

Scroll to Top